Stay updated on Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page
- Check6 days agoChange DetectedThe study record history shows the trial was terminated by the sponsor due to lack of efficacy, with updates to Study Status and Recruitment Status reflected across the page. The latest version adds a 'Results Posted' indicator and references the revised record (Revision: v3.5.4) dated 2026-05-12.SummaryDifference0.9%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe record history adds a new revision entry (v3.5.3). It replaces the previous v3.5.2 and indicates an administrative update to the study record.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedVersion 3.5.2 adds comprehensive study data sections (Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, IPDSharing, Eligibility, Arms and Interventions, Study Design, Study Description, Study Status, Study Identification, Recruitment Status). It updates the revision timeline to reflect the new changes (Revision: v3.5.2, dated 2026-03-25).SummaryDifference2%

- Check49 days agoChange DetectedThe history now shows 'Results Submitted' replacing 'No Results Posted'. The entry updates the record to indicate that study results have been submitted.SummaryDifference0.1%

- Check63 days agoChange DetectedSite revision updated to v3.5.0, replacing the prior v3.4.3.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision label updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

Stay in the know with updates to Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.